Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the middle east: Results from the edge study

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 149-155

  Saab, Charles ^a   Al Saber, Feryal A ^b   Haddad, Jihad ^c   Jallo, Mahir Khalil ^d   Steitieh, Habib ^e   Bader, Giovanni ^f   Ibrahim, Mohamed ^g  

^a Sacre Coeur Hospital Baabda   (Lebanon)

^b BAHRAIN DEFENCE FORCE HOSPITAL   (Bahrain)

^c Division of endocrinology Department of internal Medicine Prince Hamaza Hospital   (Jordan)

^d GULF MEDICAL UNIVERSITY   (United Arab Emirates)

^e New Mowasat Hospital   (Kuwait)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Novartis Pharma services AG   (United Arab Emirates)

Author keywords

Dipeptidyl peptidase 4; Middle East; Oral antidiabetic drugs; Real world; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; BAHRAIN; BODY WEIGHT DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; JORDAN; KUWAIT; LEBANON; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OMAN; PALESTINE; UNITED ARAB EMIRATES; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PREVALENCE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADAMANTANE; ADULT; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MIDDLE EAST; NITRILES; ODDS RATIO; PREVALENCE; PYRROLIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924607557     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S73703     Document Type: Article

References (26)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–321.
2. Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S. Diabetes in the Middle-East and North Africa: an update for 2013 for the IDF Diabetes Atlas. Diabetes Res Clin Pract. 2014;103:218–222.
3. Alhyas L, McKay A, Balasanthiran A, Majeed A. Quality of type 2 diabetes management in the states of the Cooperation Council for the Arab States of the Gulf: a systematic review. PLoS One. 2011;6:e22186.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35:1364–1379.
5. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–1255.
6. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–548.
7. Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab. 2011;13:193–203.
8. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar effcacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12:780–789.
9. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week effcacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–166.
10. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775–783.
11. Mathieu C, Barnett AH, Brath H, et al. Effectiveness and tolerability of oral glucose-lowering therapies in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013;67:947–956.
12. International Diabetes Federation 2013. IDF Diabetes Atlas. 6th ed. Available from: http://www.idf.org/diabetesatlas/data-visualisations. Accessed March 4, 2014.
13. Mendivil CO, Márquez-Rodríguez E, Angel ID, et al. Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study. Curr Med Res Opin. 2014;30:1769–1776.
14. Wangnoo SK, Bader G, Gawai A, Singh S. Effectiveness and tolerability of vildagliptin in Indian patients with type 2 diabetes mellitus: results from EDGE – a real-world observational study. Indian J Clin Pract. 2013;24:537–642.
15. Zabetian A, Keli HM, Echouffo-Tcheugui JB, Narayan KM, Ali MK. Diabetes in the Middle East and North Africa. Diabetes Res Clin Pract. 2013;101:106–122.
16. Al-Maskari F, El-Sadig M, Al-Kaabi JM, et al. Knowledge, attitude and practices of diabetic patients in the United Arab Emirates. PLoS One. 2013;8:e52857.
17. Göke R, Bader G, Dworak M. Real-life effectiveness and tolerability of vildagliptin and other oral glucose-lowering therapies in patients with type 2 diabetes in Germany. Diabetes Ther. 2014;5:183–191.
18. Nilsson PM, Brath H, Penfornis A, et al. Real life effectiveness and safety of vildagliptin compared with other OADs in European type 2 diabetes mellitus patients: results from the EDGE study. Diabetologia. 2014;57 Suppl 1:S1–S366.
19. Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Effcacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 2014;57:1304–1307.
20. Mirzazadeh A, Baradaran HR, Haghdoost AA, Salari P. Related factors to disparity of diabetes care in Iran. Med Sci Monit. 2009;15: PH32–PH36.
21. Mahfouz EM, Awadalla HI. Compliance to diabetes self- management in rural El-Mina, Egypt. Cent Eur J Public Health. 2011;19: 35–41.
22. Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12:495–509.
23. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485–494.
24. Rathmann W, Kostev K, Gruenberger JB, Dworak M, Bader G, Giani G. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013;15:55–61.
25. Al-Arouj M, Hassoun AA, Medlej R, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67: 957–963.
26. Hassoun A, Al-Arouj M, Ibrahim M. The effect of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study. Available from: http://www. researchgate.net/publication/259389442_The_First_Clinical_Con-gress_of_the_Gulf_Chapter_of_the_American_Association_of_Clini-cal_Endocrinologists_October_3_rd_-5_th_2013_St_Regis_Hotel_ Abu_Dhabi_United_Arab_Emirates. Accessed January 8, 2015.